We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
-20.31%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$268M
AUM Growth
-$125M
Cap. Flow
-$27.2M
Cap. Flow %
-10.13%
Top 10 Hldgs %
57.14%
Holding
61
New
14
Increased
11
Reduced
11
Closed
14

Top Buys

Rank Stock Value
1
AVTX icon
Avalo Therapeutics
AVTX
+$8.46M
2
EPZM
Epizyme, Inc
EPZM
+$7.06M
3
IMGN
Immunogen Inc
IMGN
+$6.2M
4
ABEO icon
Abeona Therapeutics
ABEO
+$3.93M
5
AIMT
Aimmune Therapeutics
AIMT
+$3.88M

Top Sells

Rank Stock Value
1
AGIO icon
Agios Pharmaceuticals
AGIO
+$10M
2
AMAG
AMAG Pharmaceuticals
AMAG
+$8.4M
3
XENE icon
Xenon Pharmaceuticals
XENE
+$7.01M
4
AMRN
Amarin Corp
AMRN
+$6.38M
5
RARE icon
Ultragenyx Pharmaceutical
RARE
+$6.11M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ETON icon
26
Eton Pharmaceutcials
ETON
$1.79B
$3.2M 1.19%
+523,000
New +$3.21M
ACAD icon
27
Acadia Pharmaceuticals
ACAD
$5.12B
$3.15M 1.18%
195,000
– –
TCDA
28
DELISTED
Tricida, Inc. Common Stock
TCDA
$2.9M 1.08%
123,000
+72,000
+141% +$2.07M
DNTH icon
29
Dianthus Therapeutics
DNTH
$6.24B
$2.88M 1.07%
31,563
-13,750
-30% -$1.87M
CDTX
30
DELISTED
Cidara Therapeutics
CDTX
$2.82M 1.05%
60,000
– –
ATXI
31
DELISTED
Avenue Therapeutics, Inc. Common Stock
ATXI
$2.68M 1%
+441
New +$2.11M
TGTX icon
32
TG Therapeutics
TGTX
$8.53B
$2.25M 0.84%
550,000
+200,000
+57% +$994K
PBYI icon
33
Puma Biotechnology
PBYI
$477M
$2.04M 0.76%
+100,000
New +$3M
EIDX
34
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$1.93M 0.72%
+140,000
New +$1.77M
MGNX icon
35
MacroGenics
MGNX
$260M
$1.91M 0.71%
+150,000
New +$2.52M
CMTA
36
DELISTED
Clementia Pharmaceuticals Inc.
CMTA
$1.76M 0.66%
150,000
+1,168
+0.8% +$14.5K
ZYME icon
37
Zymeworks
ZYME
$2.07B
$1.54M 0.58%
+105,000
New +$1.38M
COLL icon
38
Collegium Pharmaceutical
COLL
$820M
$1.37M 0.51%
+80,000
New +$1.37M
VRDN icon
39
Viridian Therapeutics
VRDN
$2.71B
$1.17M 0.44%
25,667
-67,380
-72% -$3.9M
CTIC
40
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$1.03M 0.38%
1,400,000
-150,000
-10% -$246K
PLX icon
41
Protalix BioTherapeutics
PLX
$210M
$777K 0.29%
250,000
– –
ODT
42
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$690K 0.26%
+49,000
New +$763K
SIOX
43
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$577K 0.22%
+72,500
New +$1.05M
DERM
44
DELISTED
Dermira, Inc.
DERM
$539K 0.2%
75,000
-22,400
-23% -$245K
ASRT
45
DELISTED
Assertio
ASRT
$433K 0.16%
+2,000
New +$600K
ARQL
46
DELISTED
Arqule Inc
ARQL
$358K 0.13%
200,000
-350,000
-64% -$1.34M
BLRX
47
BioLineRX
BLRX
$12.1M
$109K 0.04%
417
– –
AGIO icon
48
Agios Pharmaceuticals
AGIO
$2.05B
– –
-130,000
Closed -$10M
ARDX icon
49
Ardelyx
ARDX
$986M
– –
-650,000
Closed -$2.83M
CLLS
50
Cellectis
CLLS
$358M
– –
-110,000
Closed -$3.1M
1
2
3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q4 2018 Portfolio in Review

As of Q4 2018, Opaleye Management held 61 positions worth $268M, down 32% from $393M the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Opaleye Management withdrew a net $27.2M in Q4 2018, closing 14 positions and reducing 11 holdings. Its most notable exit was Agios Pharmaceuticals, an estimated $10M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Opaleye Management opened a new position in Avalo Therapeutics worth $6.21M.

  • Opaleye Management's largest Q4 2018 buy was Avalo Therapeutics: 759 shares worth $6.21M.
  • Opaleye Management added most to Epizyme, Inc in Q4 2018, an estimated $7.06M increase.
  • Opaleye Management's biggest Q4 2018 reduction was Amarin Corp, cutting an estimated $6.38M.
  • Opaleye Management fully exited Agios Pharmaceuticals in Q4 2018, selling an estimated $10M.
  • Opaleye Management's ten largest holdings make up 57% of its $268M portfolio in Q4 2018.
  • Opaleye Management opened 14 new positions and closed 14 in Q4 2018.
  • Opaleye Management's portfolio value fell 32% quarter-over-quarter to $268M.

Based on Opaleye Management's 13F filing for Q4 2018, filed 14 Feb 2019.